TD Cowen Reaffirms Hold Rating for Marinus Pharmaceuticals (NASDAQ:MRNS)

TD Cowen reiterated their hold rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note issued to investors on Friday morning, Benzinga reports.

MRNS has been the subject of a number of other research reports. LADENBURG THALM/SH SH cut shares of Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 14th. EF Hutton Acquisition Co. I upgraded Marinus Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th. HC Wainwright reiterated a “buy” rating and set a $11.00 price objective on shares of Marinus Pharmaceuticals in a report on Wednesday, August 14th. JMP Securities reissued a “market perform” rating on shares of Marinus Pharmaceuticals in a research note on Thursday. Finally, StockNews.com raised shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, October 4th. Eight analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $6.07.

Marinus Pharmaceuticals Stock Up 36.9 %

Shares of Marinus Pharmaceuticals stock opened at $0.41 on Friday. Marinus Pharmaceuticals has a 12 month low of $0.26 and a 12 month high of $11.26. The business has a fifty day simple moving average of $1.54 and a 200 day simple moving average of $1.56. The stock has a market cap of $22.31 million, a PE ratio of -0.15 and a beta of 1.14.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). The company had revenue of $8.06 million during the quarter, compared to the consensus estimate of $9.05 million. Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. During the same period last year, the company earned ($0.61) earnings per share. Analysts expect that Marinus Pharmaceuticals will post -1.93 EPS for the current fiscal year.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. abrdn plc boosted its stake in shares of Marinus Pharmaceuticals by 146.1% during the 3rd quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock worth $4,679,000 after buying an additional 1,578,329 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in Marinus Pharmaceuticals by 70.3% during the third quarter. Assenagon Asset Management S.A. now owns 444,185 shares of the biopharmaceutical company’s stock valued at $782,000 after purchasing an additional 183,396 shares during the last quarter. Point72 DIFC Ltd bought a new position in Marinus Pharmaceuticals in the second quarter valued at approximately $28,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Marinus Pharmaceuticals during the 2nd quarter worth approximately $64,000. Finally, AQR Capital Management LLC boosted its holdings in shares of Marinus Pharmaceuticals by 70.3% in the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 12,934 shares during the last quarter. 98.80% of the stock is currently owned by institutional investors and hedge funds.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.